top of page

Destiny’s SA trial shows fast acting antibiotic too quick for disease resistance

Destiny Pharma, a UK clinical stage drug company, found its antibacterial drug, exeporfinium chloride (XF-73), demonstrated a rapid, anti-staphylococcal effect (killed the bacteria) after just 1 day, showing a statistical difference against placebo, in their US clinical trial.

Click on this link for more information.


for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page